CTC Pancreatic Adenocarcinoma

University of Zurich (UZH)

Status and phase

Completed

Phase 4

Conditions

Adenocarcinoma

Pancreatic Neoplasms

Circulating Tumor Cells

Treatments

Drug: Desflurane

Study type

Interventional

Funder types

Other

Identifiers

NCT02335151

2016 -00448

Details and patient eligibility

About

Proportion of circulating tumor cells (CTC) in the postoperative phase after curative tumor removal of pancreatic cancer will be determined and correlated to the accordance of anesthesia (desflurane versus propofol)

Full description

This prospective, randomized study will be conducted over a 36-month period to investigate whether commonly used anesthetics (volatile versus intravenous) have an effect on the changes or occurrence of CTC in patients suffering from primary pancreatic cancer undergoing curative surgery. The specific research question is if there are changes of the CTC count in the postoperative phase in the desflurane group (intervention) compared to the propofol one (control). A secondary question is if these changes can be correlated to tumor outcome.

Enrollment

86 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 to 85
ASA I-III ( American Society of Anesthesiologists)
Resectable pancreatic adenocarcinoma
Primary surgery
No neoadjuvant therapy
Written informed consent

Exclusion criteria

Metastatic disease
Other than primary surgery (recurrence, reconstruction)
Pre-operative chemotherapy
Chronic opioid use
Known hypersensitivity or suspected allergy to propofol, soya or egg proteins
Known hypersensitivity to volatile anaesthetics (malignant hyperthermia)
Pregnancy
Breast feeding
Enrolment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion